Standard BioTools Inc.
General ticker "LAB" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $448.3M (TTM average)
Standard BioTools Inc. does not follow the US Stock Market performance with the rate: -24.4%.
Estimated limits based on current volatility of 3.3%: low 0.62$, high 0.66$
Factors to consider:
- Total employees count: 389 (-52.4%) as of 2025
- China accounted for 12.8% of revenue in the fiscal year ended 2025-12-31
- US accounted for 33.3% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Operational and conduct risks, Operating losses, Market acceptance, Construction delays, Market competition
- Current price 38.7% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.03$, 2.17$]
- 2026-12-31 to 2027-12-31 estimated range: [0.95$, 2.04$]
Financial Metrics affecting the LAB estimates:
- Positive: with PPE of -12.8 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
- Positive: -51.61 < Industry operating profit margin (median), % of -29.60
- Positive: 69.38 < Shareholder equity ratio, % of 74.73 <= 81.92
- Positive: Interest expense per share per price, % of 0 <= 0.07
- Negative: Industry earnings per price (median), % of -3.46 <= 0
- Negative: negative Net income
Short-term LAB quotes
Long-term LAB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $106.34MM | $174.43MM | $85.33MM |
| Operating Expenses | $182.94MM | $349.67MM | $195.58MM |
| Operating Income | $-76.60MM | $-175.24MM | $-110.25MM |
| Non-Operating Income | $2.40MM | $36.92MM | $13.55MM |
| Interest Expense | $4.57MM | $3.32MM | $0.03MM |
| R&D Expense | $25.95MM | $62.41MM | $25.99MM |
| Income(Loss) | $-74.20MM | $-138.31MM | $-96.70MM |
| Taxes | $0.45MM | $0.57MM | $-37.88MM |
| Other Income(Loss) | $0.00MM | $0.00MM | $-16.07MM |
| Net Income(Loss)* | $-74.66MM | $-138.88MM | $-74.90MM |
| Stockholders Equity | $-148.05MM | $471.72MM | $424.29MM |
| Inventory | $20.53MM | $40.74MM | $19.98MM |
| Assets | $323.07MM | $612.35MM | $567.75MM |
| Operating Cash Flow | $-43.29MM | $-143.45MM | $-74.34MM |
| Capital expenditure | $2.83MM | $8.36MM | $8.30MM |
| Investing Cash Flow | $20.24MM | $363.17MM | $27.41MM |
| Financing Cash Flow | $-6.81MM | $-102.62MM | $0.57MM |
| Earnings Per Share** | $-0.94 | $-0.39 | $-0.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.